Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Toby Gamlen

PhD Molecular Virology, BSc (Hons) Microbiology and Immunology

Research Assistant

Prior to joining the Gene Medicine group in October 2017 I undertook my doctoral studies in the Molecular Virology group at the University of Leeds investigating the induction of apoptosis by flavivirus proteins. Subesquently, I have under taken post doctoral research into the sub-cellular localization of the SARS N protein, the involvement of Helicobacter pylori infection in the development of iron deficiency and the role excess glucose in the bloodstream plays in impairing thrombolysis in patients with diabetes. 

I am currently funded by the Wellcome Trust, focused on the development, optimisation and production of lentiviral gene therapy vectors for disease treatment. Using Lentivirus pseudotyped with F and HN proteins, the vector can be targeted to cells in the lung. Delivery of functional copies of disease-related genes should correct cellular protein expression, allowing application for treatment of lung diseases, including Surfactant deficiencies. Further elements of this work are focused on utilizing lentiviral vectors to drive the secretion of protective anti-influenza antibodies as a mechanism for passive immunisation. 

My work is also concerned with the production and characterisation of viral vectors and the assessment of vector quality as our group prepares for a first-in-human clinical trial of a lentiviral vector treatment for Cystic Fibrosis.